Tricitrates SF Oral Solution should be taken diluted in water, followed by additional water, if desired. Palatability is enhanced if chilled before taking. 3 to 6 teaspoonfuls (15 to 30 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician. 1 to 3 teaspoonfuls (5 to 15 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician. 2 ...
Rx ONLY
Tricitrates SF Oral Solution is a stable and pleasant-tasting oral systemic alkalizer containing potassium citrate, sodium citrate, and citric acid in a sugar-free, non-alcoholic base.
Tricitrates SF Oral Solution contains in each teaspoonful (5 mL):
| POTASSIUM CITRATE Monohydrate | 550 mg |
| SODIUM CITRATE Dihydrate | 500 mg |
| CITRIC ACID Monohydrate | 334 mg |
Each mL contains 1 mEq potassium ion and 1 mEq sodium ion and is equivalent to 2 mEq bicarbonate (HCO3).
Inactive Ingredients: FD&C Yellow No. 6, flavoring, polyethylene glycol, propylene glycol, purified water, sodium benzoate, and sorbitol solution.
Potassium citrate and sodium citrate are absorbed and metabolized to potassium bicarbonate and sodium bicarbonate, thus acting as systemic alkalizers. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of the citrates are excreted in the urine unchanged.
Tricitrates SF Oral Solution is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders. This product is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urine pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate and sodium citrate do not neutralize the gastric juice or disturb digestion.
Severe renal impairment with oliguria or azotemia, untreated Addison's disease, or severe myocardial damage. In certain situations, when patients are on a sodium-restricted diet, the use of potassium citrate may be preferable; or, when patients are on a potassium-restricted diet, the use of sodium citrate may be preferable.
Should be used with caution by patients with low urinary output or reduced glomerular filtration rates unless under the supervision of a physician. Aluminum-based antacids should be avoided in these patients. Patients should be directed to dilute adequately with water and, preferably, to take each dose after meals, to minimize the possibility of gastrointestinal injury associated with oral ingestion of potassium salt preparations and to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, peripheral and pulmonary edema, and toxemia of pregnancy.
Concurrent administration of potassium-containing medication, potassium-sparing diuretics, angiotensin-converting enzyme (ACE) inhibitors, or cardiac glycosides may lead to toxicity. Periodic examination and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.
Tricitrates SF Oral Solution is generally well tolerated without any unpleasant side effects when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of hyperkalemia or alkalosis, especially in the presence of hypocalcemia. Potassium intoxication causes listlessness, weakness, mental confusion, and tingling of extremities.
Tricitrates SF Oral Solution should be taken diluted in water, followed by additional water, if desired. Palatability is enhanced if chilled before taking.
3 to 6 teaspoonfuls (15 to 30 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician.
1 to 3 teaspoonfuls (5 to 15 mL), diluted in water, four times a day, after meals and at bedtime, or as directed by a physician.
2 to 3 teaspoonfuls (10 to 15 mL), diluted with water, taken four times a day, will usually maintain a urinary pH of 6.5-7.4. 3 to 4 teaspoonfuls (15 to 20 mL), diluted with water, taken four times a day, will usually maintain a urinary pH of 7.0-7.6 throughout most of the 24 hours without unpleasant side effects. To check urine pH, HYDRION Paper (pH 6.0-8.0) or NITRAZINE Paper (pH 4.5-7.5) are available and easy to use.
Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions. Overdosage with potassium salts may cause hyperkalemia and alkalosis, especially in the presence of renal disease.
Tricitrates SF Oral Solution (orange colored, raspberry flavored) is supplied in the following oral dosage form: NDC 0121-0677-16 (16 fl oz bottles).
Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from excessive heat and freezing.
SHAKE WELL BEFORE USING.
DISTRIBUTED BY:
ATLANTIC BIOLOGICALS CORP.
20101 N.E 16TH PLACE
MIAMI, FL 33179
NDC 17856-0677-01
Tricitrates SF
Oral Solution
550mg/500mg/334mg per 5 mL
Dosage per Cup: 30mL CUP 72
A SUGAR-FREE SYSTEMIC ALKALIZER
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 309317 | citric acid 334 MG / potassium citrate 550 MG / sodium citrate 500 MG in 5 mL Oral Solution | PSN | 1 |
| 309317 | citric acid 66.8 MG/ML / potassium citrate 110 MG/ML / sodium citrate 100 MG/ML Oral Solution | SCD | 1 |
| 309317 | citric acid 334 MG / potassium citrate 550 MG / sodium citrate 500 MG per 5 ML Oral Solution | SY | 1 |
| 309317 | Citric Acid 66.8 MG/ML / K+ citrate 110 MG/ML / sodium citrate 100 MG/ML Oral Solution | SY | 1 |
| 309317 | Citric Acid 66.8 MG/ML / Pot citrate 110 MG/ML / sodium citrate 100 MG/ML Oral Solution | SY | 1 |
| Class | Version | Type | Effective |
|---|---|---|---|
| ANHYDROUS CITRIC ACID Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| ce6d5c06-3ae0-18a6-d5b3-8cd3cc0f8906 | Product name | 7 | 20210625 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0677-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-e761-f424-e053-dadaa90a57ce | Tricitrates SF Oral Solution |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0677-1 | TRICITRATES | 50 in 1 BOX, UNIT-DOSE | SOLUTION | 50 | 1 | |
| 17856-0677-1 | TRICITRATES | 30 mL in 1 CUP | SOLUTION | 30 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0677 | TRICITRATES (POTASSIUM CITRATE, SODIUM CITRATE, AND CITRIC ACID MONOHYDRATE) SOLUTION [ATLANTIC BIOLOGICALS CORP.] | 1 | Legacy NDC, 2 package rows | 20180926_d9e6b333-852b-4ddc-a3b7-32994201318e.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0121-0677-16 | ML - Milliliter | 0121-0677 | dede80bd-4a6a-49f8-8397-6a4f798ef8bf | 1 | 2013-02-13 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17856-0677 | 17856-0677-1 |
| 0121-0677 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| POTASSIUM CITRATE | EE90ONI6FF | ACTIB |
| SODIUM CITRATE | 1Q73Q2JULR | ACTIB |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | ACTIM |
| FD&C YELLOW NO. 6 | H77VEI93A8 | IACT |
| POLYETHYLENE GLYCOLS | 3WJQ0SDW1A | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| SORBITOL | 506T60A25R | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TRICITRATES | POTASSIUM CITRATE, SODIUM CITRATE, AND CITRIC ACID MONOHYDRATE | PAI Holdings, LLC dba PAI Pharma | 2ecb42a2-82f1-456b-8f1e-02c2d0a7b5ad | 2024-11-15 | Warnings, Adverse reactions | 0121-0677 |
| bf4b98cb-eacf-4489-ac73-319e8cb04625 | d9e6b333-852b-4ddc-a3b7-32994201318e | 2018-08-21 | Warnings, Adverse reactions | bf4b98cb-eacf-4489-ac73-319e8cb04625 d9e6b333-852b-4ddc-a3b7-32994201318e |
Adverse event summaries are temporarily unavailable. Other product information remains available.